Jefferies has decreased its price target on Humana HUM following 2011 guidance that was lower than expected.
In a note to clients, Jefferies writes, "'11 EPS guidance range of $5.35-$5.55 was 12% below our est. Consistent with its historical approach, Humana bids its MA plans according to its 15% Solution (underwriting margin) target. Thus, guidance is based on a 5% Medicare margin in '11 from 6.5% in '10. Commercial medical cost trends reverting to normal levels also cut into EPS. These two factors alone are a $1.20 EPS drag."
Jefferies is lowering their 2011 revenue and EPS estimates by 2% and 10% respective and they are reducing their price target from $65 to $61.
HUM is trading at $56.81.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in